权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Systematic Characterization of Small Nucleolar RNAs in Cancer

癌症中小核仁 RNA 的系统表征

基本信息

批准号：
10914508
负责人：
Leng Han
金额：
$ 41.47万
依托单位：
INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS
依托单位国家：
美国
项目类别：
财政年份：
2023
资助国家：
美国
起止时间：
2023-09-01 至 2026-08-31
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10914508
关键词：
Antisense Oligonucleotides Attenuated Biological Biological Markers Biological Models Biomedical Research Breast Cancer Cell Breast Cancer cell line Cancer Patient Cell Proliferation Clinical Communities Computing Methodologies Data Development Diagnostic Drug resistance Exhibits FDA approved Fatty acid glycerol esters Foundations Future Genetic Genetic Transcription Goals Growth In Vitro Individual Invaded Malignant Neoplasms Mammary Tumorigenesis Mammary gland Molecular Multiomic Data Outcome Pathway interactions Patient-Focused Outcomes Patients Pharmaceutical Preparations Play Process Prognosis Proliferating Quantitative Trait Loci RNA RNA-targeting therapy Research Research Personnel Role Sampling Signal Pathway Signal Transduction Small Nucleolar RNA Solid Neoplasm System The Cancer Genome Atlas Therapeutic Transcription Alteration Work Xenograft procedure cancer drug resistance cancer initiation cancer subtypes cancer type clinically relevant clinically significant data portal data resource deep learning diagnostic value differential expression disease diagnostic drug response prediction effective therapy genetic variant improved in vivo individual response insight large scale data malignant breast neoplasm mammary mouse model novel prognostic prognostic value refractory cancer response success survival outcome targeted cancer therapy targeted treatment therapeutic RNA therapeutic target treatment strategy triple-negative invasive breast carcinoma tumor tumorigenesis user-friendly

项目摘要

Abstract Despite recent advancements in treatment options for cancer, a majority of cancer types continue to lack fully characterized and effective targeted therapies. This insufficiency has resulted in the demand for alternative, previously unconsidered treatment approaches to improve disease diagnostics, prognoses, and patient survival outcomes. Recently, we performed integrative analysis for small nucleolar RNA (snoRNAs) in a large number of patient samples and identified 46 snoRNAs that exhibit broad-spectrum clinical significance with 12 or more types of cancer. We developed a data portal, snoRNA in cancers (SNORic), which allows researchers to explore the significance of individual snoRNAs in cancer. SNORic has been accessed >100,000 times since its release in 2017, suggesting its broad impact in the biomedical research community. We provided initial genetic evidence indicating that elevated expression of snoRNAs facilitated the tumorigenesis of mammary gland malignancies. Mechanistically we demonstrated that SNORD46 plays important roles in promoting the initiation, growth, invasion and progression of TNBC. Therefore, elucidation of the roles of snoRNAs in promoting tumorigenesis serves as the first step in the development of a novel class of snoRNA-based biomarkers and therapeutic targets. Our central hypothesis is that snoRNAs serve as essential RNA targets in promoting cancer initiation, progression, and drug resistance, which could be attenuated in vivo by an antisense oligonucleotide-based targeted therapy. In specific aim 1, we will delineate the diagnostic and prognostic values of these snoRNAs in triple-negative breast cancer (Aim 1.1). We will demonstrate the molecular mechanism that these snoRNAs promote TNBC cell proliferation, mobility and invasion (Aim 1.2). We will demonstrate that antisense oligonucleotide-based snoRNA targeted therapy effectively inhibits TNBC growth in vivo (Aim 1.3). We will evaluate and interpret causal effects through molQTL analysis (Aim 1.4). In specific aim 2, we will determine the role of three snoRNAs in breast cancer drug resistance (Aim 2.1). We will understand the molecular mechanisms for drug resistance through multi-omics data (Aim 2.2). To expand our perspective on drug resistance, we will predict the drug response from individual snoRNA expression with the augmentation of deep learning (Aim 2.3). We will study the drug responses effects among snoRNA-based subtypes (Aim 2.4). We will build a user-friendly data portal for releasing the date generated through integrative analysis (Aim 2.5). This study will significantly advance the prognostic, diagnostic, and therapeutic potential of snoRNAs; the absence of this research work will greatly hinder the realization of snoRNA-based therapeutic considerations for cancer patients.

抽象的尽管癌症治疗方案最近取得了进展，但大多数癌症类型仍然缺乏充分的治疗方法具有特色且有效的靶向治疗。这种不足导致了对替代品的需求，以前未考虑的改善疾病诊断、预后和患者的治疗方法生存结果。最近，我们对大核仁 RNA (snoRNA) 进行了综合分析。大量患者样本并鉴定出 46 种具有广谱临床意义的 snoRNA，其中 12 种或更多类型的癌症。我们开发了一个数据门户，癌症中的 snoRNA (SNORic)，它允许研究人员探索单个 snoRNA 在癌症中的重要性。自此以来，SNORic 的访问次数已超过 100,000 次它于 2017 年发布，表明它在生物医学研究界产生了广泛的影响。我们提供了初步的遗传证据表明 snoRNA 表达升高促进乳腺肿瘤发生腺体恶性肿瘤。我们从机制上证明了 SNORD46 在促进 TNBC 的起始、生长、侵袭和进展。因此，阐明 snoRNA 在促进肿瘤发生是开发一类基于 snoRNA 的新型药物的第一步生物标志物和治疗靶点。我们的中心假设是 snoRNA 作为促进癌症发生的重要 RNA 靶标，进展和耐药性，可以通过基于反义寡核苷酸的体内减弱靶向治疗。在具体目标 1 中，我们将描述这些 snoRNA 的诊断和预后价值三阴性乳腺癌（目标 1.1）。我们将展示这些 snoRNA 的分子机制促进 TNBC 细胞增殖、迁移和侵袭（目标 1.2）。我们将证明反义基于寡核苷酸的 snoRNA 靶向治疗可有效抑制体内 TNBC 生长（目标 1.3）。我们将通过 molQTL 分析评估和解释因果效应（目标 1.4）。在具体目标 2 中，我们将确定三种 snoRNA 在乳腺癌耐药性中的作用（目标 2.1）。我们将了解分子通过多组学数据了解耐药机制（目标 2.2）。扩大我们对毒品的看法耐药性，我们将通过个体 snoRNA 表达的增强来预测药物反应深度学习（目标 2.3）。我们将研究基于 snoRNA 的亚型之间的药物反应效应（目标 2.4）。我们将建立一个用户友好的数据门户，用于发布综合分析生成的数据（目标2.5）。这项研究将显着提高 snoRNA 的预后、诊断和治疗潜力；这缺乏这项研究工作将极大地阻碍基于 snoRNA 的治疗考虑的实现对于癌症患者。